PL3347002T3 - Leczenie choroby alzheimera w konkretnej populacji pacjentów - Google Patents

Leczenie choroby alzheimera w konkretnej populacji pacjentów

Info

Publication number
PL3347002T3
PL3347002T3 PL16845181.3T PL16845181T PL3347002T3 PL 3347002 T3 PL3347002 T3 PL 3347002T3 PL 16845181 T PL16845181 T PL 16845181T PL 3347002 T3 PL3347002 T3 PL 3347002T3
Authority
PL
Poland
Prior art keywords
alzheimer
disease
treatment
patient population
specific patient
Prior art date
Application number
PL16845181.3T
Other languages
English (en)
Inventor
Susan ABUSHAKRA
Aidan POWER
Martin TOLAR
John Hey
Jeremy Yu
Petr Kocis
Original Assignee
Alzheon, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58240195&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3347002(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alzheon, Inc. filed Critical Alzheon, Inc.
Publication of PL3347002T3 publication Critical patent/PL3347002T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL16845181.3T 2015-09-10 2016-09-09 Leczenie choroby alzheimera w konkretnej populacji pacjentów PL3347002T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562216404P 2015-09-10 2015-09-10
US201662290287P 2016-02-02 2016-02-02
US201662302027P 2016-03-01 2016-03-01
US201662365809P 2016-07-22 2016-07-22
PCT/US2016/051091 WO2017044840A1 (en) 2015-09-10 2016-09-09 Methods of treating neurodegenerative disorders in a particular patient population

Publications (1)

Publication Number Publication Date
PL3347002T3 true PL3347002T3 (pl) 2023-11-13

Family

ID=58240195

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16845181.3T PL3347002T3 (pl) 2015-09-10 2016-09-09 Leczenie choroby alzheimera w konkretnej populacji pacjentów

Country Status (21)

Country Link
US (3) US11191742B2 (pl)
EP (2) EP4275750B1 (pl)
JP (4) JP6789579B2 (pl)
KR (2) KR102547164B1 (pl)
CN (3) CN108289870A (pl)
AU (1) AU2016319107B2 (pl)
CA (1) CA2997376C (pl)
DK (1) DK3347002T3 (pl)
ES (1) ES2952727T3 (pl)
FI (1) FI3347002T3 (pl)
HR (1) HRP20230809T1 (pl)
HU (1) HUE062511T2 (pl)
LT (1) LT3347002T (pl)
MD (1) MD3347002T2 (pl)
MX (2) MX392677B (pl)
PL (1) PL3347002T3 (pl)
PT (1) PT3347002T (pl)
RS (1) RS64481B1 (pl)
SI (1) SI3347002T1 (pl)
SM (1) SMT202300250T1 (pl)
WO (1) WO2017044840A1 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102645633B1 (ko) 2014-03-21 2024-03-11 알제온, 인크. 신경학적 장애를 치료하는 방법
EP4275750B1 (en) * 2015-09-10 2026-05-06 Alzheon, Inc. Treatment of alzheimer's disease in a particular patient population
CN114805211B (zh) 2017-03-21 2024-08-23 润佳（苏州）医药科技有限公司 同位素富集3-氨基-1-丙磺酸衍生物、药物组合物及其用途
CN110003058B (zh) 2018-01-04 2022-01-25 润佳（苏州）医药科技有限公司 3-((l-缬氨酰基)氨基)-3,3-二氘-1-丙磺酸晶型、制备方法及用途
SI3829568T1 (sl) * 2018-08-01 2024-02-29 Alzheon, Inc. Derivati sulfopropanojske kisline za zdravljenje nevrodegenerativnih motenj
HUE070101T2 (hu) * 2018-08-01 2025-05-28 Alzheon Inc 3-Szulfopropánsav neurodegeneratív rendellenességek kezelésére
CN111170901A (zh) * 2018-11-13 2020-05-19 润佳（苏州）医药科技有限公司 3-((l-缬氨酰基)氨基)-1-丙磺酸晶型、制备方法及其用途
UA129160C2 (uk) * 2019-06-17 2025-01-29 Алзхеон, Інк. Спосіб лікування хвороби альцгеймера
CN116059192B (zh) 2019-11-13 2024-10-29 润佳（苏州）医药科技有限公司 同位素富集的3-氨基-1-丙磺酸及其衍生物的用途
JP2024542844A (ja) * 2021-12-09 2024-11-15 アルツェオン・インコーポレーテッド アルツハイマー病の処置に使用されるａｌｚ－８０１
WO2023150381A1 (en) * 2022-02-07 2023-08-10 Alzheon, Inc. Alz-801 for use in treating a covid-19 associated neurological symptom

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
JP3265577B2 (ja) 1992-10-13 2002-03-11 デューク・ユニバーシティ アポリポ蛋白ｅの４型イソ型の測定法
US20050031651A1 (en) 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
US20050142191A1 (en) 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
US20060079578A1 (en) 2003-06-23 2006-04-13 Julie Laurin Pharmaceutical formulations of amyloid inhibiting compounds
US20070010573A1 (en) 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
SG145784A1 (en) 2003-08-11 2008-09-29 California Inst Of Techn Microfluidic large scale integration
CA2611586A1 (en) 2005-04-12 2007-06-21 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
DK2089417T3 (en) * 2006-10-12 2015-03-23 Bhi Ltd Partnership Methods, Compounds, Compositions and Vehicles for Delivery of 3-Amion-1-Propanesulfonic Acid
KR101450356B1 (ko) 2006-11-24 2014-10-15 에이씨 이뮨 에스.에이. 알츠하이머와 같은 아밀로이드 또는 아밀로이드-유사 단백질과 관련된 질환의 치료를 위한 ｎ-(메틸)-1ｈ-피라졸-3-아민, ｎ-(메틸)-피리딘-2-아민 및 ｎ-(메틸)-티아졸-2-아민 유도체
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP2322163A1 (en) * 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
US20120009125A1 (en) 2010-07-06 2012-01-12 Lombard Jay L Apoe4 and apoj biomarker-based prevention and treatment of dementia
ES2705027T3 (es) * 2010-08-19 2019-03-21 Buck Institute For Age Res Métodos de tratamiento del deterioro cognitivo leve (DCL) y trastornos relacionados
EP2847218A4 (en) * 2012-05-08 2015-12-30 Univ Ramot APOE4 ANTIBODY FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
HUE044737T2 (hu) * 2013-05-06 2019-11-28 Baxalta Inc Alzheimer-kór szubpopulációk kezelése egyesített immunglubulin G-vel
CA2938466C (en) * 2014-02-08 2021-11-02 Genentech, Inc. Methods of treating alzheimer's disease
KR102645633B1 (ko) 2014-03-21 2024-03-11 알제온, 인크. 신경학적 장애를 치료하는 방법
EP4275750B1 (en) * 2015-09-10 2026-05-06 Alzheon, Inc. Treatment of alzheimer's disease in a particular patient population

Also Published As

Publication number Publication date
EP4275750B1 (en) 2026-05-06
JP2025065545A (ja) 2025-04-17
HUE062511T2 (hu) 2023-11-28
MX392677B (es) 2025-03-24
EP4275750A2 (en) 2023-11-15
CA2997376A1 (en) 2017-03-16
US20230414541A1 (en) 2023-12-28
WO2017044840A1 (en) 2017-03-16
EP3347002A4 (en) 2019-04-24
FI3347002T3 (fi) 2023-08-10
JP2022145949A (ja) 2022-10-04
AU2016319107A1 (en) 2018-03-22
RS64481B1 (sr) 2023-09-29
MD3347002T2 (ro) 2023-10-31
AU2016319107B2 (en) 2021-02-25
SMT202300250T1 (it) 2023-09-06
KR20180051561A (ko) 2018-05-16
KR20220042480A (ko) 2022-04-05
KR102547164B1 (ko) 2023-06-22
HRP20230809T1 (hr) 2023-10-27
CN116712422A (zh) 2023-09-08
EP3347002A1 (en) 2018-07-18
DK3347002T3 (da) 2023-08-14
LT3347002T (lt) 2023-09-11
CA2997376C (en) 2024-05-14
JP6789579B2 (ja) 2020-11-25
PT3347002T (pt) 2023-07-27
MX2022003128A (es) 2022-08-02
JP2020200352A (ja) 2020-12-17
HK1257874A1 (en) 2019-11-01
MX2018003023A (es) 2018-06-06
US20220096406A1 (en) 2022-03-31
CN108289870A (zh) 2018-07-17
KR102412997B1 (ko) 2022-06-23
EP3347002B1 (en) 2023-06-07
JP2018526407A (ja) 2018-09-13
EP4275750A3 (en) 2024-01-17
ES2952727T3 (es) 2023-11-03
US11191742B2 (en) 2021-12-07
CN116712423A (zh) 2023-09-08
SI3347002T1 (sl) 2023-12-29
JP7128536B2 (ja) 2022-08-31

Similar Documents

Publication Publication Date Title
CY2023010I2 (el) Προφαρμακα καρβιντοπας και l-ντοπας και η χρηση τους στην αγωγη της νοσου parkinson
PL3347002T3 (pl) Leczenie choroby alzheimera w konkretnej populacji pacjentów
IL285722A (en) Methods for treating alzheimer's disease
MA45192A (fr) Traitement d'association
IL247085B (en) Methods for treating Alzheimer's disease
HUE054783T2 (hu) Pridopidin Huntington-kór kezelésében
IL246999B (en) Methods for treating Alzheimer's disease
HUE063369T2 (hu) Vegyületek Alzheimer-kór kezelésében történõ alkalmazásra APOE4+/+ betegekben
EP3556368A4 (en) THERAPEUTIC FOR ONYCHOMYCOSIS
IL263433A (en) Methods for treating alzheimer's disease
LT3463351T (lt) Parkinsono ligos gydymas
CY1127309T1 (el) Ebselen για χρηση στη θεραπεια της νοσου meniep
IL259710A (en) Compositions and methods of treatment for mvid and related diseases
PT3413870T (pt) Igmesina para utilização no tratamento de doença de alzheimer
PL3137097T3 (pl) Leczenie i profilaktyka choroby Alzheimera (AD)
IL254252A0 (en) History of Tetrahydrofuran-Oahe Aminohydrothiazine Usefulness in the Treatment of Alzheimer's Disease
KR20180085033A (ko) 피부 질환 치료용 약학적 제형 및 이의 제조 방법
DK3137094T3 (da) Behandling og forebyggelse af alzheimers sygdom (ad)
IL262902A (en) Prion protein-dendrimer conjugates for use in treatment of alzheimer disease
PT3137093T (pt) Tratamento e prevenção da doença de alzheimer (da)
PL3302463T3 (pl) Zastosowanie 3 deoksyantocyjanidyn w leczeniu chorób oczu
EP3322481A4 (en) TREATMENT OF ROTATOR COIL DRESSES
GB201511453D0 (en) Treatment of alzheimer's disease